The stock of INmune Bio Inc (INMB) has seen a -14.98% decrease in the past week, with a -21.46% drop in the past month, and a -9.98% decrease in the past quarter. The volatility ratio for the week is 8.56%, and the volatility levels for the past 30 days are at 6.69% for INMB. The simple moving average for the past 20 days is -13.83% for INMB’s stock, with a 5.89% simple moving average for the past 200 days.
Is It Worth Investing in INmune Bio Inc (NASDAQ: INMB) Right Now?
Moreover, the 36-month beta value for INMB is 1.95. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for INMB is 11.74M and currently, short sellers hold a 12.30% of that float. On April 04, 2024, INMB’s average trading volume was 81.05K shares.
INMB) stock’s latest price update
INmune Bio Inc (NASDAQ: INMB)’s stock price has gone decline by -7.76 in comparison to its previous close of 10.95, however, the company has experienced a -14.98% decrease in its stock price over the last five trading days. Seeking Alpha reported 2024-03-28 that INmune Bio, Inc. (INMB) Q4 2023 Earnings Call Transcript
Analysts’ Opinion of INMB
Many brokerage firms have already submitted their reports for INMB stocks, with Robert W. Baird repeating the rating for INMB by listing it as a “Outperform.” The predicted price for INMB in the upcoming period, according to Robert W. Baird is $16 based on the research report published on June 01, 2023 of the previous year 2023.
B. Riley Securities, on the other hand, stated in their research note that they expect to see INMB reach a price target of $7, previously predicting the price at $14. The rating they have provided for INMB stocks is “Neutral” according to the report published on May 24th, 2022.
Maxim Group gave a rating of “Buy” to INMB, setting the target price at $42 in the report published on July 07th of the previous year.
INMB Trading at -16.39% from the 50-Day Moving Average
After a stumble in the market that brought INMB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.48% of loss for the given period.
Volatility was left at 6.69%, however, over the last 30 days, the volatility rate increased by 8.56%, as shares sank -17.01% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -9.58% lower at present.
During the last 5 trading sessions, INMB fell by -14.98%, which changed the moving average for the period of 200-days by +9.54% in comparison to the 20-day moving average, which settled at $11.62. In addition, INmune Bio Inc saw -10.30% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at INMB starting from Juda Scott, who purchase 7,000 shares at the price of $6.95 back on Nov 10 ’23. After this action, Juda Scott now owns 37,000 shares of INmune Bio Inc, valued at $48,650 using the latest closing price.
Schroeder Timothy j, the Director of INmune Bio Inc, sale 10,000 shares at $11.01 during a trade that took place back on Jul 12 ’23, which means that Schroeder Timothy j is holding 82,187 shares at $110,085 based on the most recent closing price.
Stock Fundamentals for INMB
Current profitability levels for the company are sitting at:
- -191.88 for the present operating margin
- 1.0 for the gross margin
The net margin for INmune Bio Inc stands at -194.33. The total capital return value is set at -0.77. Equity return is now at value -61.09, with -43.24 for asset returns.
Based on INmune Bio Inc (INMB), the company’s capital structure generated 0.21 points at debt to capital in total, while cash flow to debt ratio is standing at -1.15.
Currently, EBITDA for the company is -29.74 million with net debt to EBITDA at 0.85. When we switch over and look at the enterprise to sales, we see a ratio of 1010.69. The receivables turnover for the company is 0.06for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.16.
Conclusion
To wrap up, the performance of INmune Bio Inc (INMB) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
